Gwo Xi Stem Cell Applied Technology (6704) Stock Overview
Develops stem cell technology for patients with unmet medical needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
6704 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Gwo Xi Stem Cell Applied Technology Co. , Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$21.50 |
| 52 Week High | NT$33.65 |
| 52 Week Low | NT$18.85 |
| Beta | 0.088 |
| 1 Month Change | 0.94% |
| 3 Month Change | -5.49% |
| 1 Year Change | -20.37% |
| 3 Year Change | -53.26% |
| 5 Year Change | n/a |
| Change since IPO | -53.31% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6704 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | 2.4% | 8.8% | 7.8% |
| 1Y | -20.4% | 47.9% | 109.8% |
Return vs Industry: 6704 underperformed the TW Biotechs industry which returned 42.7% over the past year.
Return vs Market: 6704 underperformed the TW Market which returned 103.8% over the past year.
Price Volatility
| 6704 volatility | |
|---|---|
| 6704 Average Weekly Movement | 4.3% |
| Biotechs Industry Average Movement | 6.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in TW Market | 12.1% |
| 10% least volatile stocks in TW Market | 2.6% |
Stable Share Price: 6704 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 6704's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 55 | Chuan-Feng Chiu | www.gwoxi.com.tw |
Gwo Xi Stem Cell Applied Technology Co. , Ltd develops stem cell technology for patients with unmet medical needs. Its products under development include GXHPC1, an autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of liver cirrhosis; and GXNPC1, an autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of chronic stroke. The company is also developing GXCPC1, an allogeneic adipose-derived stem cells therapy in phase I/II clinical trials for use in the treatment of osteoarthritis; and GXIPC1, an allogeneic adipose-derived stem cells therapy in phase I clinical trials for use in the treatment of diabetes.
Gwo Xi Stem Cell Applied Technology Co. , Ltd Fundamentals Summary
| 6704 fundamental statistics | |
|---|---|
| Market cap | NT$2.07b |
| Earnings (TTM) | -NT$80.52m |
| Revenue (TTM) | NT$187.02m |
Is 6704 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6704 income statement (TTM) | |
|---|---|
| Revenue | NT$187.02m |
| Cost of Revenue | NT$55.05m |
| Gross Profit | NT$131.97m |
| Other Expenses | NT$212.49m |
| Earnings | -NT$80.52m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.84 |
| Gross Margin | 70.56% |
| Net Profit Margin | -43.05% |
| Debt/Equity Ratio | 55.3% |
How did 6704 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/18 05:57 |
| End of Day Share Price | 2026/06/18 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Gwo Xi Stem Cell Applied Technology Co. , Ltd is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.